Bispecific T-cell engager antibody (CD3×CD19) that redirects T cells to lyse CD19-positive B-ALL cells.
Recombinant bispecific antibody (CD3×CD19) that binds CD3 on T cells and CD19 on B cells, bringing them into proximity to form an immune synapse and activate T-cell cytotoxicity, leading to perforin/granzyme-mediated lysis of CD19-positive B-ALL cells.
Blinatumomab bridges CD3 on T cells to CD19 on target cells, activating T cells to kill CD19+ cells via perforin/granzyme-mediated cytolysis.
Humanized, Fc‑engineered anti‑CD19 IgG1 monoclonal antibody that targets CD19 on B cells and mediates tumor killing via ADCC, ADCP, and direct pro‑apoptotic signaling; used for R/R DLBCL in combination with lenalidomide.
Fc‑engineered humanized anti‑CD19 IgG1 monoclonal antibody that binds CD19 on B cells and depletes CD19+ malignant B cells by enhancing FcγR engagement to drive ADCC and ADCP, and by inducing direct pro‑apoptotic signaling.
The anti-CD19 IgG1 binds CD19 on B cells and kills via Fc gamma receptor–mediated ADCC (e.g., NK cells) and ADCP (macrophages), and can also trigger direct pro-apoptotic signaling in CD19+ cells.
Chimeric anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity/phagocytosis, and induction of apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre‑B and mature B lymphocytes, triggering complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and phagocytosis, and direct apoptosis to deplete CD20-positive B cells.
Rituximab binds CD20 on B cells and kills via complement-dependent cytotoxicity, Fc-mediated ADCC/ADCP by immune effector cells, and can directly induce apoptosis of CD20+ cells.
CD20×CD3 bispecific T-cell–engaging antibody that redirects T cells to kill malignant CD20-positive B cells.
CD20×CD3 bispecific antibody that simultaneously binds CD3 on T cells and CD20 on B cells, forming an immunologic synapse that activates and redirects T cells to kill CD20-positive B cells via CTL-mediated cytotoxicity.
Glofitamab links CD3 on T cells to CD20 on target cells, forming an immunologic synapse that activates T cells to kill CD20+ cells via perforin/granzyme-mediated cytolysis and apoptosis.
Glycoengineered type II anti-CD20 monoclonal antibody with enhanced ADCC/ADCP and direct cell-death activity; used as a pre-dose with glofitamab.
Glycoengineered, humanized type II anti‑CD20 IgG1 that binds CD20 on B cells; afucosylated Fc increases affinity for FcγRIIIa, enhancing ADCC and ADCP, and it induces strong direct, caspase‑independent cell death of CD20+ B cells (with limited complement activation).
Binds CD20 on B cells and triggers effector functions via its Fc (enhanced FcγRIIIa binding) leading to ADCC by NK cells and ADCP by macrophages, and also induces strong direct, caspase-independent cell death (with limited complement activation).